MYC

[Hepatology] The therapeutic efficacy and the molecular pathways targeted by TVB3664, either alone or with tyrosine kinase inhibitors or the checkpoint inhibitor anti-PD-L1 antibody, were assessed in human HCC cell lines and multiple oncogene-driven HCC mouse models.

[Evidence-Based Complementary and Alternative Medicine] Scientists investigated the cellular activities of α-mangostin, human cancer cells, MCF-7 and MCF-7-CR cells, by treating them with α-mangostin to measure the cellular responses, including cytotoxicity, protein-protein interaction, and protein expression.

[Clinical and Translational Oncology] Pretreated specimens were evaluated by immunohistochemistry for programmed cell death protein 1 and its ligand, densities of tumor infiltrative lymphocytes, as well as c-MYC and Ki-67 expressions.

[FASEB Journal] Scientists found estrogen receptor beta could increase the CSC population via altering the circPHACTR4/miR-34b-5p/c-Myc signaling.

[Molecular Carcinogenesis] Investigators assessed the stage-specific expression of zinc transporters (ZNTs) belonging to the ZNT (SLC30A) and Zrt- and Irt-like protein (SLC39A) solute-carrier family in the prostate tissues of different genetically engineered mouse models of prostate cancer, their age-matched wild-type controls, and 104 prostate core biopsies from human patients with different pathological lesions.

[Oncogene] BEST4 is a member of the bestrophin protein family that plays a critical role in human intestinal epithelial cells. Scientists investigated the role and clinical significance of BEST4 in CRC.